ASCO 2026: Revolution Medicines Pancreatic Data Called 'Unprecedented'; Ivonescimab 34% OS

Three major trade outlets independently called Revolution Medicines' pancreatic cancer data "unprecedented" — in a tumor type that has humbled every drug class thrown at it for thirty years.

Meanwhile, a thirty-four percent survival gain in lung cancer is getting picked apart, Pfizer just wrote a ten-and-a-half-billion-dollar check for China-sourced oncology assets, and a hepatitis B dataset that should be front-page news got completely buried by ASCO. We have a lot to unpack.

Welcome to The Pharma Closeout Weekend Edition for Sunday, May thirty-first, twenty-twenty-six. I'm Alex Mercer.

And I'm Maya Patel. It was a massive week. Let's take it apart.

We start at ASCO, where Revolution Medicines landed the single most-discussed dataset of the entire meeting. BioPharma Dive used the word "unprecedented" and said the data point to a paradigm shift. Endpoints News simply wrote, quote, "Yes, Revolution Medicines' pancreatic cancer data are that good." That kind of editorial convergence across independent outlets doesn't happen by accident — the magnitude of effect is clearly large enough to have moved the room.

Pancreatic ductal adenocarcinoma has buried more drug candidates than nearly any other solid tumor. Gemcitabine-based regimens have anchored treatment for decades, and the survival curves have barely moved. If RevMed's RAS-targeted approach is generating the kind of responses that justify this language, it represents mechanistic validation — not just a single clinical result.

And the competitive framing is already taking shape. Fierce Biotech separately reported that RevMed is confident in its RAS leadership position even as rivals square up. So this isn't just a clinical milestone — it's a flag-planting exercise at the biggest stage in oncology.

I'd push back on the coronation. KRAS-targeted responses in pancreatic cancer have historically been measurable but difficult to sustain. What separates a genuine inflection point from a compelling conference abstract is whether these responses hold at twelve months and beyond. The initial signal may be extraordinary, but durability will determine whether RevMed has built a franchise or landed a headline.

I'll concede the durability question is open. But three editorially independent outlets converging on the same superlative language — that tells you the initial effect size cleared a very high bar for this tumor type.

Agreed on signal strength. And if durability holds, the downstream effects go well beyond RevMed. Every company with a KRAS program just got both validated and benchmarked in a single presentation.

Here's the strategic read: RevMed's data effectively reprices every RAS-targeted asset in development. If you're running business development and evaluating KRAS programs this week, the licensing terms just changed.

And the clinical question for medical oncologists won't be whether to use these agents — it'll be when in the treatment sequence, and in which molecularly defined subsets. That conversation starts at ASCO and plays out over the next two years of practice-changing trials.

That sequencing question applies to the deal landscape too — because the companies writing the biggest checks right now are essentially betting on which clinical conversations will matter most three years from now. The headline number this week: ten-point-five billion dollars. Pfizer and Innovent Biologics announced a global strategic collaboration covering up to twelve antibody cancer drug programs, per Endpoints News. Let's bring in Marcus Webb for the structural read.

And the pattern is accelerating. Separately, Lilly announced acquisitions of three vaccine biotechs for up to three-point-eight billion dollars combined — pushing its diversification well beyond the metabolic franchise.

The Innovent structure tells you something specific about Pfizer's internal calculus. Twelve programs means the majority are early-stage. Pfizer is buying pipeline breadth and optionality, not late-stage de-risked assets. That's a very different risk profile, and it reflects exactly where their oncology pipeline needs reinforcement.

Two more items to flag. On the commercial side, CVS struck an obesity drug deal with Lilly that includes the new oral Foundayo and restores Zepbound coverage — putting Lilly on equal footing with Novo Nordisk. That erases what had been a meaningful payer-access edge for Novo — the differentiation battle now moves entirely to clinical outcomes and patient retention data. And in leadership news, Allogene's CEO David Chang is stepping down after eight years at the cell therapy maker. That's a founder-era departure, and it raises immediate questions about strategic continuity at a company still searching for its commercial inflection point.

The Allogene transition matters, but the clinical story that dominated the rest of ASCO was ivonescimab. Akeso and Summit Therapeutics presented Harmoni-6 data showing their bispecific PD-1/VEGF antibody plus chemo delivered a thirty-four percent improvement in overall survival versus the comparator arm in lung cancer. That number exceeded expectations.

Summit has positioned ivonescimab as a direct Keytruda challenger in first-line non-small cell lung cancer. A thirty-four percent OS improvement is a number that gets boardroom attention at Merck — that's their franchise drug under pressure.

It does — but the trial was conducted entirely in China, and the detailed data are already being dissected. The distribution of PD-L1 expression levels, the proportion of patients harboring EGFR driver mutations — those characteristics shift meaningfully between Chinese and Western trial populations. They directly affect comparator-arm performance. So a thirty-four percent relative benefit means different things depending on what the control was doing. The global regulatory path depends on whether this effect replicates in a more heterogeneous patient population.

Pfizer also had a strong ASCO showing. Three datasets worth flagging quickly. Per their press releases: the Braftovi regimen nearly doubled median progression-free survival in metastatic colorectal cancer — we've been tracking Braftovi since the Phase 3 win earlier this year and flagged the NCCN guideline update as the key downstream catalyst. Talzenna plus Xtandi improved radiographic progression-free survival by more than fifty percent in metastatic prostate cancer. And the seven-year Lorbrena CROWN analysis showed the longest progression-free survival reported to date in advanced non-small cell lung cancer.

That Talzenna-Xtandi prostate dataset is the backdrop for the J&J-Pfizer rivalry that played out across consecutive ASCO days. Pfizer presented first, effectively setting the benchmark — then J&J positioned Erleada with new data the following day. The sequencing of those presentations was strategic, not coincidental.

Beyond the big-name oncology data, a handful of other ASCO reads deserve mention. Incyte positioned its Monjuvi combination for first-line DLBCL — that's a commercial expansion play from relapsed-refractory into a much larger treatment-naive population. BMS unveiled data on a next-generation blood cancer drug. And Lilly presented what FiercePharma called the "final chapter" for Retevmo, teeing up a further label expansion for its RET inhibitor.

And off the ASCO floor entirely, MannKind secured FDA sign-off on pediatric expansion for Afrezza — their inhaled insulin. Smaller story by market cap, but it opens a population where needle-phobia and injection-site adherence are real barriers to achieving target glycemic control. If this changes the conversation around early insulin initiation in adolescents, the commercial upside could surprise.

Speaking of stories that could surprise — Maya, what got buried this week?

Under the radar, and genuinely lost beneath the ASCO avalanche: GSK and Ionis unveiled data for bepirovirsen in hepatitis B. Treating physicians called the findings a "historic moment." Analysts described "clear blockbuster potential." The data supported what's being characterized as a functional cure.

Functional cure in hepatitis B. Let that sit for a second. Any other week, that phrase alone headlines every outlet in the industry.

To explain why that language is so loaded — functional cure in hep B means sustained HBsAg loss off therapy. That's surface antigen clearance without ongoing treatment. The current standard of care is indefinite nucleoside analog suppression — you're managing the virus, never eliminating it. If bepirovirsen delivers durable HBsAg loss — and the hepatologists using the term "functional cure" are not a group prone to overstatement — this is a fundamental redefinition of treatment goals for one of the most prevalent chronic infections globally.

GSK and Ionis may be sitting on a franchise opportunity that the market hasn't fully priced simply because the timing collided with the biggest oncology meeting of the year. That kind of attention dislocation tends to correct quickly once the hepatology community's reaction reaches a broader audience.

The week ahead stays busy. ASCO isn't over — late-breaking abstracts drop this week, and subgroup analyses from several of the presentations we just covered could materially reshape the initial reads.

Watch the ivonescimab subgroups in particular. PD-L1-high versus PD-L1-low splits will either reinforce or undermine the global regulatory thesis. And any expanded durability or safety data from RevMed's pancreatic program will tell us whether the superlatives from this weekend hold up under scrutiny.

Beyond ASCO, Pfizer-Innovent program-level details should start to emerge — which of those twelve antibody programs are closest to clinical milestones. That prioritization will signal where the near-term value sits in what is otherwise a very broad portfolio bet.

And keep bepirovirsen on your list. If peer-reviewed data follow the conference presentation quickly, hepatitis B goes from under-the-radar to top-story in a single publication cycle.

Tremfya and Venclyxto both secured expanded indications last week — we're watching for additional label decisions as the second half of twenty-twenty-six takes shape. The regulatory tempo is picking up, and the companies that stacked multiple catalysts into this window are about to find out whether that strategy paid off.

That wraps our weekend closeout. Revolution Medicines rewriting the pancreatic cancer playbook. Ivonescimab's thirty-four percent OS win drawing equal parts excitement and skepticism. Pfizer deploying ten-and-a-half billion dollars into China's biotech pipeline. And a hepatitis B functional cure result from GSK and Ionis that deserves far more airtime than it's getting. This was one of those weeks that reminds you why this industry never stops being fascinating. If this briefing saves you time, follow us on Spotify and drop a rating — we're back tomorrow with more from ASCO and whatever else lands.

Go enjoy your Sunday evening. See you tomorrow.